U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H32N2O4
Molecular Weight 436.5433
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SB-423562

SMILES

CC(C)(CC1CC2=CC=CC=C2C1)NC[C@@H](O)COC3=C(C=CC(CCC(O)=O)=C3)C#N

InChI

InChIKey=NJBFJCJKWWIKRD-HSZRJFAPSA-N
InChI=1S/C26H32N2O4/c1-26(2,14-19-11-20-5-3-4-6-21(20)12-19)28-16-23(29)17-32-24-13-18(8-10-25(30)31)7-9-22(24)15-27/h3-7,9,13,19,23,28-29H,8,10-12,14,16-17H2,1-2H3,(H,30,31)/t23-/m1/s1

HIDE SMILES / InChI

Molecular Formula C26H32N2O4
Molecular Weight 436.5433
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 00:36:48 GMT 2023
Edited
by admin
on Sat Dec 16 00:36:48 GMT 2023
Record UNII
615K7YBS59
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SB-423562
Common Name English
BENZENEPROPANOIC ACID, 4-CYANO-3-((2R)-3-((2-(2,3-DIHYDRO-1H-INDEN-2-YL)-1,1-DIMETHYLETHYL)AMINO)-2-HYDROXYPROPOXY)-
Systematic Name English
SB-423562-A
Code English
SHP-635
Code English
NPSP-795
Code English
4-CYANO-3-((2R)-3-((2-(2,3-DIHYDRO-1H-INDEN-2-YL)-1,1-DIMETHYLETHYL)AMINO)-2-HYDROXYPROPOXY)BENZENEPROPANOIC ACID
Systematic Name English
Code System Code Type Description
MANUFACTURER PRODUCT INFORMATION
SB-423562
Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
PRIMARY NPS Pharmaceuticals (NASDAQ: NPSP) has initiated a Phase 2a study to evaluate the safety and tolerability of NPSP795 in adult patients with Autosomal Dominant Hypocalcemia (ADH), an ultra-rare genetic disorder of calcium homeostasis. ADH is caused by mutations of the calcium-sensing receptor (CaSR) gene that increase the sensitivity of the receptor to serum calcium. NPSP795 is a selective calcium receptor antagonist, which binds to the CaSR and decreases its sensitivity to serum calcium. Its mechanism of action is believed to restore the normal physiological action of the CaSR and address the underlying molecular defect in ADH to return to normal calcium homeostasis. The company expects to report preliminary top-line data from the study in late 2014 or early 2015.
FDA UNII
615K7YBS59
Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
PRIMARY
CAS
351490-27-2
Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
PRIMARY
PUBCHEM
9910902
Created by admin on Sat Dec 16 00:36:48 GMT 2023 , Edited by admin on Sat Dec 16 00:36:48 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Here we describe two novel, short-acting calcium-sensing receptor antagonists (SB-423562 and its orally bioavailable precursor, SB-423557) that elicit transient PTH release from the parathyroid gland in several preclinical species and in humans. In an ovariectomized rat model of bone loss, daily oral administration of SB-423557 promoted bone formation and improved parameters of bone strength at lumbar spine, proximal tibia and midshaft femur. Chronic administration of SB-423557 did not increase parathyroid cell proliferation in rats. In healthy human volunteers, single doses of intravenous SB-423562 and oral SB-423557 elicited transient elevations of endogenous PTH concentrations in a profile similar to that observed with subcutaneously administered PTH. Both agents were well tolerated in humans. Transient increases in serum calcium, an expected effect of increased parathyroid hormone concentrations, were observed post-dose at the higher doses of SB-423557 studied.
Related Record Type Details
ACTIVE MOIETY
Chronic administration of SB-423557 did not increase parathyroid cell proliferation in rats. In healthy human volunteers, single doses of intravenous SB-423562 and oral SB-423557 elicited transient elevations of endogenous PTH concentrations in a profile similar to that observed with subcutaneously administered PTH. Both agents were well tolerated in humans. Transient increases in serum calcium, an expected effect of increased parathyroid hormone concentrations, were observed post-dose at the higher doses of SB-423557 studied. These data constitute an early proof of principle in humans and provide the basis for further development of this class of compound as a novel, orally administered bone-forming treatment for osteoporosis.